Anxiety disorders are serious and common mental diseases, yet there is still a need for the development of more effective anxiolytics with better safety profiles than benzodiazepines and serotonin reuptake inhibitors. The serotonergic and noradrenergic systems have reciprocal interactions and are intricately related to the pathogenesis of anxiety. In this study, the anxiolytic-like effect of the novel compound ACH-000029, 3-(2-(4-(2-methoxyphenyl) piperazine-1-yl) ethyl) quinazoline-4(3H)-one, is reported. This compound acts at selected serotonergic (5-HT1A and 5-HT1D partial agonism and 5-HT2A antagonism) and α-adrenergic (α-1A, 1B and 1D antagonism) receptors, with good selectivity over other G-protein-coupled receptors. ACH-000029 exhibited high blood-brain barrier permeation and acute anxiolytic effects in the marble burying (MB) and light-dark box (LDB) models of anxiety over the dose ranges of 8-32 mg/kg i.p. and 16-30 mg/kg p.o. The anxiolytic activity was comparable to that observed for serotonin reuptake inhibitors (paroxetine and fluoxetine) and benzodiazepines (alprazolam, diazepam and clobazam). The analysis of the whole-brain c-fos expression following oral dosing showed that ACH-000029 regulated regions highly associated with the processing of environmental stimuli and anxiety behavior, such as the amygdala, paraventricular nucleus of the thalamus, retrosplenial dorsal, pallidum, bed nuclei of the stria terminalis, and locus ceruleus. No safety concerns were identified for ACH-000029 in the functional observational battery up to 50 mg/kg i.p. and in the nonprecipitated withdrawal test up to 30 mg/kg p.o. twice daily for 20 days. This work supports the further development of ACH-000029 as a drug candidate for the treatment of anxiety disorders. The analysis of the in vitro pharmacology and brain regions regulated by this compound may also lead to the exploration of other indications within the psychiatry field.
Introduction
Anxiety disorders constitute a significant burden worldwide, as determined by healthcare expenditures, loss in work productivity, and personal suffering. They are described as excessive responses to stimulation perceived as dangerous, with symptoms interfering with daily activities (Cryan and Sweeney, 2011) . Although there are useful anxiety treatments (Farach et al., 2012) , there is still a need for more effective anxiolytics with better safety profiles than benzodiazepines (BZDs) and selective serotonin reuptake inhibitors (SSRIs). BZDs are gamma-aminobutyric acid (GABA)-positive allosteric modulators with adverse effects such as sedation, memory disturbances, and abuse liability (Griffin et al., 2013) . Conversely, SSRI increases synaptic serotonin levels and presents limitations due to its delayed onset of action and sexual dysfunction in 40% of patients (Bandelow et al., 2017; Higgins et al., 2010) .
The search for novel anxiolytic compounds has focused on targeting specific neurotransmitter systems: the noradrenaline (NE), 5-hydroxytryptamine (5-HT or serotonin), GABA, neuropeptides, glutamate, and endocannabinoid systems (Murrough et al., 2015) . The regulation of 5-HT and NE neurotransmission is considered particularly promising to discover new anxiolytic drugs, since these systems are involved in both the pathogenesis and symptoms of psychiatric disorders (McCorvy and Roth, 2015; Griebel and Holmes, 2013; Kalk et al., 2010; Ressler and Nemeroff, 2000) .
The NE and 5-HT systems have reciprocal interactions and modulate one another's actions in the brain. For example, SSRIs reduce the firing rate of NE neurons in the long but not in the short term, whereas α₁-https://doi.org/10.1016/j.pnpbp.2019.109707 Received 5 February 2019; Received in revised form 18 May 2019; Accepted 17 July 2019 adrenoreceptor antagonism modulates the anxiolytic effect of the SSRI citalopram (Takamura et al., 2012) . NE neurotransmission is also involved in the residual anxiety symptoms observed in SSRI-treated patients, such as fatigue, decreased concentration, and cognitive impairment. Indeed, the function of NE neurotransmission in the prefrontal cortex is described by an inverted U shape, in which low levels result in cognitive impairment, inattention, and drowsiness, while high levels also produce cognitive impairment and anxiety. Therefore, optimal levels of NE neurotransmission are required to mitigate anxiety disorders and maintain cognitive performance (Blier and Briley, 2011) , which are currently not achieved with the SSRIs.
This unmet need supports the potential of developing novel anxiolytic drugs acting at specific 5-HT and NE receptors to achieve a higher efficacy with fewer side effects. For example, buspirone -a 5-HT1A partial agonist and D2 receptor antagonist -was the first anxiolytic compound to be developed as an alternative to BZDs and SSRIs. The 5-HT1A and 5-HT2A receptors were previously described as drug targets for anxiety (Celada et al., 2013) , since the disruption of the 5-HT1A and 5-HT2A receptor signaling induces anxiolytic-like behavior in animal models (Overstreet et al., 2003; Weisstaub et al., 2006) . Moreover, the use of 5-HT2A receptor blockers combined with SSRIs decreases the firing activity of NE neurons in an acute fashion, which may improve the early clinical efficacy (Szabo and Blier, 2002) . Interestingly, 5HT1A and 5HT2A both also seem to affect the anxiety-like behavior in posttraumatic-stress disorder (PTSD) mice (Xiang et al., 2017) .
Drugs acting at α-adrenergic receptors have been shown to be effective to treat specific anxiety-related conditions. For instance, the α1 adrenergic inverse agonist prazosin improves nightmare symptoms in PTSD patients (Breen et al., 2017) and anxiety behavior in response to alcohol deprivation (Rasmussen et al., 2017) . Moreover, α-adrenergic receptor variants were recently identified as susceptibility factors for generalized anxiety disorder (Zhang et al., 2017) . This evidence highlights the potential of modulating α-adrenergic receptors to achieve superior efficacy in the treatment of anxiety disorders.
This study aimed at characterizing a novel anxiolytic compound that acts at selected 5-HT and α1 adrenergic receptors. The in vitro effects of ACH-000029 on 5-HT and NE receptors, as well as its acute anxiolytic-like activity in animal models and whole-brain c-fos expression following its oral administration, were investigated. Pharmacokinetic and safety studies were also performed to support the potential of ACH-000029 as a drug candidate.
Materials and methods

Drugs
ACH-000029 ( Fig. 1 ) was prepared in a dimethyl sulfoxide (DMSO) stock solution and diluted in appropriate buffers for the in vitro assays. Buspirone, alprazolam, fluoxetine, paroxetine, escitalopram, chlordiazepoxide, diazepam, and clobazam were purchased from Sigma-Aldrich (St. Louis, MO, USA). The vehicle was physiological saline with 0.2% hydroxypropyl methylcellulose (HPMC) for the behavioral studies with i.p. administration, distilled water with 10% polyethylene glycol 400 (PEG400) and 20% Cremophor for the functional observational battery, and distilled water with 0.2% HPMC for the remaining studies. The reference drugs for comparisons were selected from the BZD (alprazolam, diazepam and clobazam) and SSRI (fluoxetine and paroxetine) classes. The dose selection for these compounds was based on previous MB (Baretta et al., 2012; Nicolas et al., 2006) and LDB studies (Hascoët and Bourin, 1998) . ACH-000029 was assessed using doses ranging from 4 to 32 mg/kg i.p. and 0.3-30 mg/kg p.o. These dose ranges were selected based on the drug's in vitro activity and pharmacokinetic (PK) properties. Following each behavioral test, the doses were adjusted to assess the dose-response effect.
Animals
NMRI and Swiss male mice from Elevage Janvier (Le Genest-SaintIsle, France) were used in the behavioral anxiety studies. Male Rj: Wistar (Han) rats (Elevage Janvier) were used for the functional observational battery and for the nonprecipitated withdrawal tests. C57BL/6 male mice from the Cold Spring Harbor Laboratory (CSHL) were used for the brain activity mapping. The animals were grouped in polycarbonate cages on wood litter and were kept under artificial lighting (12 h) between 7:00 and 19:00 in a controlled ambient temperature of 21 ± 3°C and a relative humidity between 20 and 80%. Food and water were available ad libitum. Naïve animals were used for each test and were sacrificed by the inhalation of carbon dioxide or transcardial perfusion with saline and 4% formaldehyde following ketamine/xylazine anesthesia. The experiments were conducted during the light phase of the day (i.e., between 10 am and 4 pm). Male Wistar Han rats from Vital River (Beijing, China), C57BL/6 mice from Lingchang Biotechnology (Shanghai, China), and beagle dogs from Marshall BioResources (Beijing, China) were used for the PK studies. For the PK experiments, the animals were fasted for 12 h and then had access to food and water ad libitum 4 h post-dose. Behavioral, safety, and brain c-fos mapping experiments were performed at Neurofit (Illkirch, France), Porsolt (Le Genest-Saint-Isle, France), and Certerra (Cold Spring Harbor, USA). The experiments were conducted in compliance with animal health regulations (Council Directive No. 2010/63/ UE and French decree No. 2013-118) , the organization's accreditation for experimentation and the recommendations of the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). The experiments were approved by Neurofit's (approval numbers 120.02 and 121.02), Porsolt's (EEPSCNS3.4M, EEPSCNS3.7M and EEPSCNS3.8R) and CSHL's (933272-15) ethical committees before initiating the studies.
In vitro potency and selectivity profile
The in vitro activity of ACH-000029 was characterized using radioligand binding and cellular functional assays for serotonergic (5-HT1A and 5-HT2A) and α-adrenergic (α1A, 1B, 1D) receptors. The ACH-000029 selectivity profile was determined using the BioPrint panel (Eurofins Pharma Discovery, France), which comprises 135 targets, including enzymes, ion channels, transporters, and receptors. The buspirone functional activity was assessed on the 5-HT1A and 5-HT2A receptors as a reference compound. The detailed experimental procedures are described in the Supplementary Information.
Drug metabolism and pharmacokinetic studies
The absorption, distribution, metabolism, and excretion (ADME) properties of ACH-000029 were assessed in vitro using aqueous thermodynamic solubility, distribution coefficient, Caco-2 permeability, metabolic stability in cryopreserved hepatocyte (rat, mice, dog, and human), and cytochrome P450 inhibition assays. In vivo PK studies were performed in C57BL/6 mice, Wistar Han rats, and beagle dogs after acute intravenous (i.v.) and oral (p.o.) administration. The brain levels of ACH-000029 were also determined in C57BL/6 mice after acute p.o. administration. The detailed experimental procedures are Fig. 1 . ACH-000029 chemical structure.
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Behavioral anxiety models
The acute anxiolytic evaluation of ACH-000029 was carried out using the LDB and MB tests. These tests were selected to verify the anxiolytic activity of ACH-000029 based on approach-avoidance conflict (LDB) and active avoidance (MB) settings (Calhoon and Tye, 2015) . Tests were also selected based on previous data showing that they can reveal the anxiolytic effects of drugs acting via 5-HT neurotransmission (Bourin, 2015; Abe et al., 1998; Ichimaru et al., 1995; Young and Johnson, 1991; Baretta et al., 2012) . Swiss strains were selected because they are commonly used in the MB and LDB tests (JimenezGomez et al., 2011; Pires et al., 2013; Ene et al., 2016; Rodriguez et al., 2017) . Outbred mice were used because their interindividual variability may contribute to the external validity due to the variability expected in the human population (Hånell and Marklund, 2014; Hsieh et al., 2017) . The animals were randomized during cage allocation after delivery. The behavioral tests were performed blind with respect to the treatment conditions, and the animals were observed during the tests to check for marked sedated behavior.
Marble-burying (MB) model
The MB model is described by Broekkamp et al. (1986) , in which rodents exposed to a novel object (marbles) bury them in the sawdust floor covering. Compounds showing anxiolytic-like activity decrease the number of buried marbles at nonsedative doses. Mice, n = 12-20 per group, were individually placed in transparent plastic cages (33 × 21 × 18 cm) with 5 cm of sawdust on the floor and 20-25 marbles grouped in the center of the cage. The cage was covered with an inverted plastic cage. The number of marbles covered by sawdust was counted at the end of a 30-min session. A marble was considered buried if at least 2/3 of it was covered by sawdust. Quantitative data is presented as the number of marbles covered with sawdust. Two separate experiments were performed, distinguished by the route of administration (i.p. or p.o.) and compound dose. The first experiment was performed with i.p. administration, 30 min before the test, using doses of 8, 16, and 32 mg/kg for ACH-000029, 1 mg/kg for alprazolam and paroxetine, and 32 mg/kg for fluoxetine. The second experiment was performed with p.o. administration, 45 min before the test, using doses of 3, 8, and 16 mg/kg for ACH-000029 and 1 mg/kg for diazepam.
Light-dark box (LDB) model
The LDB model is described by Crawley (1981) . Mice, n = 10 per group, were initially placed into the light compartment of a 2-compartment box. The light intensity was lower than 25 lx in the dark compartment and higher than 400 lx in the light compartment. The time spent in each compartment and the number of times the animals crossed between the chambers were scored during a 3-min session. Only entries with four limbs in a compartment were considered effective crossings. Two separate experiments were performed, distinguished by the route of administration (i.p. or p.o.) and dose of the compounds. The first experiment was performed with i.p. administration: ACH-000029 (4, 8 and 16 mg/kg), alprazolam (1 and 2 mg/kg), clobazam (12 mg/kg) or vehicle were administered i.p. 30 min before the test. The second experiment was performed with the p.o. administration of ACH-000029 (0.3, 1, 3, 10, and 30 mg/kg), clobazam (32 mg/kg) or vehicle 45 min before the test.
Brain c-fos mapping study
The neuronal c-fos activation in the whole mouse brain was assessed in response to an acute administration of ACH-000029. Mice, n = 6 per group, were orally treated with ACH-000029 at 30 mg/kg or vehicle and returned to their home cage. The dose was selected based on the efficacious dose observed in the LDB p.o. study. After 2.5 h, the animals were anesthetized with ketamine/xylazine and killed by transcardial perfusion with saline and 4% formaldehyde. The timepoint selection was based on the time course for maximum c-fos expression (Bojovic et al., 2015; Zangenehpour and Chaudhuri, 2002) and the standard iDISCO+ protocol (Renier et al., 2016) . The brains were dissected and postfixed, and the treatment-evoked brain activation based on the c-fos expression was evaluated using whole-brain immunohistochemistry (Osten and Margrie, 2013; Renier et al., 2016) . The ACH-000029-treated animals were compared to the vehicle group.
Functional observational battery
The method is described by Irwin (1968) and adapted to evaluate the effect of serotonin agonists per Martin et al. (1985) and Ortmann et al. (1981) . Rats, n = 6 per group, were given a single administration of the test substances and observed in simultaneous comparison with the vehicle groups. ACH-000029 (10, 32 and 50 mg/kg i.p.), escitalopram (24 mg/kg i.p.), or vehicle were administered immediately before the test. Behavioral modifications, physiological and neurotoxicity symptoms, and the rectal temperature and pupil diameter were recorded in a standardized observation grid containing the following items: death*, convulsions*, tremors*, Straub tail*, altered activity (sedation or excitation), jumping*, abnormal gait* (rolling, tip-toe), motor incoordination*, altered abdominal muscle tone, loss of grasping, akinesia, catalepsy, loss of traction, loss of balance*, writhing*, piloerection*, stereotypies* (sniffing, chewing, head movements), scratching*, altered respiration*, aggression*, altered fear/startle, altered activity to touch, ptosis, exophthalmia, loss of righting and corneal reflexes, analgesia, defecation, salivation, lacrimation, rectal temperature and pupil diameter. In addition, signs related to 5-HT receptor stimulation were scored: head twitches*, fore-paw treading*, flat body posture*, hind-limb splay (abduction)*, lower lip retraction*, and Straub/spontaneous tail flicks. Observations were performed 0, 15, 30 and 60 min after the administration of the test substances, and the symptoms marked (*) were observed continuously from 0 to 15 min after administration.
Nonprecipitated withdrawal test
The method detects nonprecipitated withdrawal symptoms upon the cessation of drug treatment (Goudie and Leathley, 1991) . Rats, n = 12 per group (2 per cage), received twice-daily administrations (at approximately 10:00 and 16:00) of the test substance for 19 days (Day 1-Day 19), with the last administration on Day 20 at approximately 10:00, and the control animals received the same number of administrations of vehicle. Following drug withdrawal, the rats were observed over an 8-day period for changes in food consumption, body weight and rectal temperature. They were also observed for behavioral and physiological manifestations: jumping, fear/startle, sniffing, wet dog shakes, writhing, ptosis, tremors, genital licks, scratching, hyperactivity, grooming, Straub tail, tiptoe gait, teeth-chattering, dyspnea, diarrhea and burying. During the withdrawal phase, animals received once-daily administrations of vehicle (at approximately 10:00). In addition to the observations taken following withdrawal, the same measures were also taken on Day 1 and Day 10 of the treatment period and during the last 3 days of treatment just before administration in the morning to evaluate the effects of the substance before drug withdrawal. Following withdrawal, the first observation was performed 24 h after the last administration and thereafter at 24-h intervals (Day 21-Day 28). For the daily measures, the animals were first scored for behavioral changes during a 5-min observation period, and they were then measured for body weight and rectal temperature. The food remaining in the food hoppers was weighed immediately after all the animals were returned to their cages (mornings only), and their food consumption over the previous 24 h was calculated. The body weight, food consumption and rectal temperature were also recorded 24 h prior to the first administration. The treatment groups were homogenized with respect to body weight measured on the day preceding the first administration. ACH-000029 was evaluated at 3 doses (3, 10 and 30 mg/kg), administered p.o., and compared with a vehicle control group. Chlordiazepoxide (64 mg/kg p.o.), paroxetine (15 and 30 mg/kg p.o.), and alprazolam (1 and 2 mg/kg p.o.), administered under the same experimental conditions, were used as comparison substances.
Statistical data analysis
The behavioral data is presented as the mean ± S.E.M. and analyzed using the one-way ANOVA with group as factor followed by Dunnett's post hoc test. Differences between the groups were considered significant if p < .05. For the brain c-fos activity mapping, statistical comparisons were done by negative binomial regression (Kim et al., 2016; Kim et al., 2015; Renier et al., 2016) . The p-values were corrected for multiple comparisons using the qvalue package in R and assuming a false discovery rate of 10% (Storey, 2003) . For the cellular functional studies, the inhibition constant (K i ), half-maximal inhibitory concentration (IC 50 ), apparent dissociation constant (K B ), half-maximal effective concentration (EC 50 ) and intrinsic activity (I.A.) values were determined by a nonlinear regression analysis of the concentration-response curves generated using Hill equation curve fitting in GraphPad Prism™ 5.0 software.
Results
Discovery of ACH-000029
Several novel quinazolinone-arylpiperazine derivatives were synthesized as part of a medicinal chemistry program at Aché Laboratórios, leading to the identification of ACH-000029. Compounds bearing quinazolinone or quinazoline scaffolds have already been described to bind to noradrenergic (Maestri et al., 2017) and serotonin receptors such as 5-HT2A (Alvarado et al., 2006) and 5-HT1A (Rádl et al., 2000) . In addition, the arylpiperazine group is a common moiety in compounds acting at the 5-HT and α-adrenergic receptors (Kowalski et al., 2011; Zajdel et al., 2004; Li et al., 2000; Fiorino et al., 2014) . The ACH-000029 synthesis is described in the Supplementary Methods.
In vitro potency and selectivity profile of ACH-000029
The ACH-000029 in vitro activity is reported in Table 1 The ACH-000029 selectivity was assessed in a broad in vitro panel. ACH-000029 exhibited a binding affinity higher than 50% at 10 μM (a standard cutoff for further investigation) for 13 out of 135 targets, in addition to the therapeutic targets (5-HT1A, 5-HT2A, α1A, and α1B). These data are depicted in Table S1 . ACH-00029 displayed partial agonism at the 5-HT1D (EC 50 = 23 nM, I.A. = 56%) and antagonism at the 5-HT2B (K B = 150 nM), α2A (K B = 98 nM), and α2C (K B = 320 nM) receptors.
In vitro ADME assays
The ACH-000029 in vitro ADME properties are displayed in Table 2 . ACH-00029 exhibited good cell permeability and aqueous solubility and fair metabolic stability. ACH-000029 showed no relevant inhibition at 10 μM for several CYP450 isoforms (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A), suggesting its low potential for drug-drug interactions. ACH-000029 also has a distribution coefficient (logD) value between 0 and 3, within the sweet spot range for bloodbrain barrier permeation (Pajouhesh and Lenz, 2005) .
Pharmacokinetic studies
The ACH-000029 in vivo PK parameters for rats, mice, and dogs after i.v. and p.o. administrations are displayed in Table 3 . The plasma concentration curves are shown in Fig. S1 . A low oral bioavailability was observed in mice and rats, (3.9% and 1.3%, respectively), but a much higher bioavailability (F = 32.2%) was found in dogs. The brain and plasma concentration curves after the acute oral dosing of ACH-000029 in mice are reported in Fig. S2 . The brain-to-plasma ratios of ACH-000029 varied between 1 and 1.88 at the 30 mg/kg and 60 mg/mg p.o. doses, confirming its high brain exposure. 
Evaluation of the anxiolytic-like activity of ACH-000029 in behavioral models
The in vitro pharmacology profile and PK properties of ACH-000029 supported its evaluation in animal models of anxiety. Due to its low oral bioavailability in rodents, ACH-000029 was initially evaluated using i.p. administration to circumvent intestinal absorption and metabolism. Then, the same tests were carried out using oral administration. The behavioral experiments were performed in the following order: MB i.p., LDB i.p., LDB p.o. and MB p.o. The acute anxiolytic effects of ACH-000029 are depicted in Figs. 2 (MB) and 3 (LDB).
In the MB i.p. (Fig. 2A) , the one-way ANOVA showed a statistically significant treatment effect (F(6,77) = 14.83, p < .0001). ACH-000029 at 8, 16 and 32 mg/kg i.p. dose-dependently decreased the number of buried marbles (−82%, −98% and − 99%, respectively) compared to the vehicle (p < .0001). The positive controls alprazolam, paroxetine, and fluoxetine also reduced the number of covered marbles (−92%, −56% and − 74%, respectively) compared to the vehicle (p < .0001). The ACH-000029 doses were reduced for the LDB i.p. experiment to better characterize its dose-response anxiolytic effect. In the LDB i.p. (Fig. 3A and B) , a significant treatment effect was observed for the time spent in the light compartment (F(6,63) = 6.29, p < .0001) and the number of transitions between the light and dark compartments (F(6,63) = 10.11, p < .0001). Alprazolam at 1 mg/ kg i.p. and ACH-000029 at 8 and 16 mg/kg i.p. increased the time spent in the light compartment by +72% (p < .05), +111% (p < .001), and + 93% (p < .01) compared to the vehicle. This was accompanied by a reduction in the number of transitions between the light and dark compartments for alprazolam at 1 (−61%; p < .01) and 2 mg/kg i.p. (−79%; p < .001) and for ACH-000029 at 4 (−53%; p < .01), 8 (−92%; p < .001), and 16 mg/kg i.p. (−83%; p < .001). ACH-000029 at 8 mg/kg and 16 mg/kg i.p. was active in both the MB and LDB models. The absence of anxiolytic effects for ACH-000029 at 4 mg/ kg i.p. is indicative of the dose-responsiveness of the compound.
Considering that LDB was the first behavioral model tested using oral administration ( Fig. 3C and D) , a broader range of ACH-000029 doses was assessed based on the previous MB i.p. and LDB i.p. results. In this study, a treatment effect was observed in the time spent in the light compartment (one-way ANOVA, F(6,63) = 7.17, p < .0001) and the number of crossings (F(6,63) = 4.13, p < .01). Clobazam at 32 mg/kg p.o. and ACH-000029 at 30 mg/kg p.o. increased the time spent in the light compartment when compared to the vehicle (+59% and + 60% respectively, p < .01), but only ACH-000029 at 30 mg/kg reduced the number of crossings, −59% (p < .01) compared to the vehicle.
In the MB p.o. (Fig. 2B) , a narrower dose range than in the LDB p.o. study was used to determine the minimum oral dose that would lead to anxiolytic effects. There was a statistically significant treatment effect (F(4,95) = 15.01, p < .0001). ACH-000029 decreased the number of marbles covered by sawdust in a dose-dependent fashion with statistical significance at 16 mg/kg p.o. (−44.2%, p < .01 in Dunnett's post hoc test) and a trend towards significance at 8 mg/kg p.o. (−28.8%, p = .052). Diazepam also reduced the number of marbles covered (−72.7%, p < .001) compared to the vehicle.
A secondary analysis was performed after removing the data from animals with marked sedation. Only groups with five or more animals were considered. In the LDB i.p., the one-way ANOVA revealed a H. Azevedo, et al. Progress in Neuropsychopharmacology & Biological Psychiatry 95 (2019) 109707 statistically significant treatment effect for the time spent in the light compartment (F(3,35) = 8.26, p < .0001; Fig. S3A ) and the number of compartment transitions (F(3,35) = 2.67, p < .05; Fig. S3B ). A statistically significant increase in the time spent in the light compartment was observed for the ACH-000029 at 16 mg/kg (+40%, p < .05), alprazolam at 1 mg/kg (+51%, p < .01) and clobazam at 12 mg/kg (+41%, p < .01) groups. ACH-000029 at 16 mg/kg also reduced the number of compartment transitions (−66%, p < .05). No animals displayed marked sedation in the MB p.o. In the MB i.p., there was a statistically significant treatment effect (F(3,33) = 4.99, p < .01; Fig.  S4 ). The animals treated with ACH-000029 at 8 mg/kg (−56%, p < .05), paroxetine at 1 mg/kg (−56%, p < .01) and fluoxetine at 32 mg/kg (−61%, p < .01) showed significant reductions in the number of buried marbles when compared to the vehicle.
Brain c-fos activity mapping
The neuronal c-fos activity was assessed following the acute dosing of ACH-000029 (30 mg/kg p.o.). The dose was selected based on the results from the LDB p.o. study. The brain regions that exhibited statistically significant differences of at least ± 30 c-fos positive cells between groups are depicted in Fig. 4 . The brain regions with increased cfos positive cells were located at the cerebral cortex (taenia tecta, anterior cingulate area), cerebral nuclei (bed nuclei of the stria terminalis and pallidum), hindbrain (inferior olivary complex, locus ceruleus), hypothalamus (lateral and median preoptic areas, anterior, paraventricular and ventromedial hypothalamic nuclei), and thalamus (midline, intermediodorsal and paraventricular nuclei of the thalamus). In contrast, the regions most downregulated were located at the cerebellum (uvula, copula pyramidis, pyramus), cerebral cortex H. Azevedo, et al. Progress in Neuropsychopharmacology & Biological Psychiatry 95 (2019) 109707 (retrosplenial dorsal, agranular insular area, anterolateral visual area), hypothalamus (periventricular hypothalamic nucleus), thalamus (anteromedial nucleus of the thalamus) and amygdala (basolateral-BLA and medial-MEA).
Functional observational battery
The functional observational battery results are summarized in Fig.  S5 . ACH-000029 at 10 mg/kg i.p. induced a slight-to-moderate decrease in activity, abnormal gait (rolling), decreased abdominal muscle tone, loss of traction, decreased reactivity to touch, and ptosis. It also induced a flat body posture, hind-limb splay and slight hypothermia. At 32 mg/ kg i.p., it induced the same signs observed at 10 mg/kg, although over a longer duration, with a stronger intensity, or in a greater number of animals. In addition, it induced tremors, jumping, akinesia, and catalepsy and it decreased fear/startle. At 50 mg/kg i.p., it induced the same signs as at 32 mg/kg, although with a stronger intensity or in a greater number of animals. In addition, it decreased respiration and induced fore-paw treading, lower-lip retraction and slight myosis. Escitalopram (24 mg/kg) induced tremors, Straub tail, a light-to-moderate decrease in activity and abnormal gait (tip-toe). Abdominal muscle tone was either decreased or increased, and reactivity to touch was mainly increased. It induced loss of traction, writhing in 2 rats, aggression and ptosis. It also induced a flat body posture, hind-limb splay and slight hypothermia.
Nonprecipitated withdrawal test
ACH-000029 did not show any withdrawal effects at the doses of 3, 10 and 30 mg/kg after the cessation of a twice-daily p.o. dosing for Fig. 4 . c-Fos mapping of brain regions regulated by ACH-000029. Brain c-fos expression was evaluated in mice (n = 6 per group) after acute oral dosing of ACH-000029 (30 mg/kg) or vehicle. Statistically significant differences between the numbers of c-fos positive neurons from the ACH-000029 and vehicle groups are displayed for the regions with a minimum average difference of ± 30 neurons. Regions are based on the Allen Brain Atlas. 20 days. Conversely, paroxetine at 15 and 30 mg/kg dose-dependently decreased the body weight, daily food consumption and rectal temperature. Alprazolam at 1 and 2 mg/kg occasionally increased daily food consumption and rectal temperature but had no effect on body weight during the treatment period. Stopping treatment with paroxetine and alprazolam induced weak withdrawal effects on Day 21, as reflected by occasional behavioral signs and decrease in the daily food consumption, respectively. Chlordiazepoxide at 64 mg/kg showed a clear discontinuation syndrome, with decreasing effects on the body weight and food consumption, and a rectal temperature increase. The results are shown in Figs. S6, S7 and S8.
Discussion
In this work, the pharmacological profile of ACH-000029 -a novel compound that modulates both 5-HT and NE neurotransmission -was characterized. The compound acts via partial agonism at the 5-HT1A and 5-HT1D receptors and antagonism at the 5-HT2A, α1A, α1B, and α1D receptors. It also displayed anxiolytic-like effects in rodent models, exceptional in vitro selectivity and is predicted to have good oral bioavailability in humans based on drug metabolism data from several animal species. Moreover, ACH-000029 showed a high brain-to-plasma ratio in mice, a must for CNS-acting drugs (Di et al., 2013) .
Drugs acting on multiple 5-HT receptors may achieve improved efficacy and a faster onset for the treatment of anxiety. Indeed, the concurrent modulation of 5-HT1A and 5-HT2A produce synergic effects in ameliorating acute anxiety symptoms (Marek et al., 2003; de Paula and Leite-Panissi, 2016) . 5-HT1A can regulate other 5-HT receptors and influence their effects on behavior (Popova and Naumenko, 2013) . The anxiolytic effect of 5-HT1A-acting compounds is influenced by their intrinsic activity, pre-or postsynaptic action and secondary messengers (Polter and Li, 2011) . The full 5-HT1A receptor agonist flibanserin, for example, exhibits antidepressant but not anxiolytic-like activity (Borsini et al., 1999) , while buspirone, a 5-HT1A partial agonist, is a clinically used anxiolytic drug (Eison and Temple, 1986) . ACH-000029 showed potent 5-HT1A partial agonism such as buspirone, with both acting via cAMP inhibition. Moreover, the partial agonism of ACH-000029 at 5-HT1D might attenuate anxiety symptoms by regulating 5-HT1D overactivation, which is reported to inhibit GABA cortical release and generate anxiogenic behavior (Orsolini et al., 2016; Amital et al., 2005) .
ACH-000029 also showed potent α1A, α1B, and α1D adrenergic antagonism, which may lead to synergic activity with 5-HT modulation in the treatment of anxiety disorders. Specifically, ACH-000029 treatment has the potential to benefit patients with stress-induced anxiety disorders such as panic disorder, PTSD, and increased anxiety following alcohol withdrawal. This is because the exaggerated activation of the hypothalamic-pituitary-adrenal stress axis induces chronic NE release and facilitates anxiety-like behavioral responses (Morilak et al., 2005) . For example, α1 receptors play a role in the decrease of the social interaction time induced by immobilization stress (Cecchi et al., 2002) .
ACH-00029 showed adequate in vitro ADME properties and limited oral bioavailability in rodents but good in vivo exposure in dogs ( Table 2 ). The in vitro metabolic stability is correlated to the in vivo extent of a compound's metabolism by scaling the intrinsic clearance using the liver weight and cellularity information (Houston, 1994) . A compound with a first-pass extraction ratio lower than 30% or higher than 70% is generally classified as slightly or highly metabolized, respectively. For rodents, the high clearance threshold values in rats and mice hepatocytes correspond to 27.5 and 17.8 μL/min/10 6 cells. The ACH-000029 clearance values greatly exceeded these thresholds (226 and 71.1, respectively). In contrast, the human and dog in vitro clearance values (CL = 21 and 13.3, respectively) were close to the boundary between high and medium clearance (19.0 and 10.5, respectively) . This suggests that ACH-000029 may exhibit an oral bioavailability of approximately 30% if only the liver clearance dominates its metabolic fate. The ACH-000029 bioavailability in dogs (F = 32.2%) was in accordance with its liver first-pass extraction ratio of 70%, predicted from hepatocyte data. The observed in vitro-in vivo correlation suggests that ACH-000029 will exhibit good bioavailability in humans.
The acute anxiolytic-like activity of ACH-000029 was confirmed in anxiety models at doses starting from 8 mg/kg i.p. and 16 mg/kg p.o. The compound was studied in the MB and LDB models, which are frequently employed to identify anxiolytic drugs (Njung'e and Handley, 1991; Bourin and Hascoet, 2003; Cryan and Sweeney, 2011) . ACH-000029's anxiolytic-like activity is comparable to that of reference compounds. In the MB, the mice i.p.-treated with ACH-000029 at 8 mg/ kg exhibited a more pronounced decrease in buried marbles than fluoxetine at 32 mg/kg. In the LDB test, the mice p.o. treated with ACH-000029 at 30 mg/kg displayed an increased time spent in the light compartment, as was observed for clobazam at 32 mg/kg. Although no direct comparison was made between buspirone and ACH-00029, the latter has the potential to be more efficacious to treat specific anxiety disorders. This is because ACH-00029 combines buspirone-like 5-HT1A-mediated anxiolytic activity with the α-adrenergic activity of prazosin. Indeed, ACH-000029 exhibited an anxiolytic response in the MB at lower doses than buspirone (Abe et al., 1998; Ichimaru et al., 1995) .
The whole-brain c-fos activity of ACH-000029 was also evaluated after oral acute administration to correlate its anxiolytic activity with the brain regions regulated by 5-HT and noradrenergic neurotransmission. The observed c-fos pattern suggests that ACH-000029 influences a brain network known to be involved in the processing of contextual stimuli with emotional valence to ultimately regulate anxiety-related behaviors (Calhoon and Tye, 2015) .
The retrosplenial dorsal and basolateral amygdala (BLA) were regions downregulated by ACH-000029. Interestingly, olanzapine (a dual 5-HT2A/D2 antagonist) reduces anxiety behavior and retrosplenial cfos-positive cells in rats subjected to chronic psychosocial stress (Stanisavljević et al., 2019) . BLA is the main input nucleus in the amygdala that receives external stimuli from the thalamus and sensory cortex. The overactivation of the amygdala is a key component of anxiety disorders, and 5-HT1A agonism or 5-HT2A antagonism in the BLA and medial amygdala (MEA) reduce conditioned fear and anxiety-like behavior (Morrison and Cooper, 2012; Clinard et al., 2015; de Paula and Leite-Panissi, 2016) . Last, the decrease in cerebellum activation highlights its potential role in the anxiolytic response of ACH-000029. The cerebellum is connected to several brain areas involved in anxiety and contributes to the overestimation of environment-related harms (Moreno-Rius, 2018 ).
An increase in the number of c-fos positive neurons was also observed in several brain regions of ACH-000029-treated animals. Some of them were shown to be activated in rat models of anxiety, such as the taenia tecta, anterior cingulate area and paraventricular nucleus of the hypothalamus (Duncan et al., 1996) . The midline thalamus (MTN), paraventricular nucleus of the thalamus (PVT), pallidum, bed nucleus of the stria terminalis (BST) and locus ceruleus (LC) were also regions activated by ACH-000029. The increased activation in the noradrenergic LC system is likewise observed for the anxiolytic 5-HT1A partial agonist buspirone (Sanghera et al., 1982) . Concurrently, the MTN and PVT project to limbic subcortical structures, such as the amygdala, nucleus accumbens and BST, and hence are critical to affective behaviors (Vertes et al., 2015) .
BST is a heterogeneous center that integrates information with emotional valence and exhibits many connections with the amygdala and hypothalamus. The anterior BST showed a larger increase in c-fos positive cells than the posterior BST in ACH-000029-treated mice. The anterior division contains several subregions and exhibits a high density of NE and 5-HT innervation (Lebow and Chen, 2016) . BST has opposing circuits that modulate both anxiogenic and anxiolytic outcomes (Daniel and Rainnie, 2016) . These behaviors depend on specific 5-HT receptor types in the anterior BST. For example, 5-HT1A autoreceptors mediate anxiolytic behavior, while 5-HT2A receptors induce anxiogenic behavior (Lebow and Chen, 2016) .
It is important to disclose that although c-fos mapping is widely used to identify activated brain regions, it does not i) provide information on the neurotransmitters involved, ii) always correlate with neuronal firing, iii) indicate whether the activation is direct or indirect, or iv) occur in all activated neurons (Appleyard, 2009) .
ACH-000029 at 10-50 mg/kg i.p. displayed a safe profile in the functional observational battery, with behavioral results equivalent to escitalopram (24 mg/kg i.p.) and buspirone (Haberzettl et al., 2014) . In the withdrawal test, ACH-000029 (3-30 mg/kg p.o.) did not exhibit any withdrawal symptoms, while paroxetine, alprazolam and chlordiazepoxide induced changes in the body weight, daily food consumption and rectal temperature. ACH-00029 induced a sedated-like behavior in some animals. BZDs and SSRIs also cause sedation in humans and animal models (Hascoët and Bourin, 1998; Marken and Munro, 2000) . Even though sedative effects are confounding factors in behavioral studies, ACH-000029 displayed anxiolytic-like effects in the MB and LDB models when the data from sedated animals were removed from the analysis. Moreover, ACH-000029 can lead to a blood pressure reduction due to its activity in α1 adrenoceptors (Cavalli et al., 1997; Tanoue et al., 2002) , which may be an underlying cause of the sedativelike effect.
Although α1 antagonism may lead to orthostatic hypotension, this adverse effect is observed for many psychiatric drugs, such as BZDs, tricyclic antidepressants, monoamine oxidase inhibitors, and atypical antipsychotics (Bandelow et al., 2017; Carvalho et al., 2016; Grugger, 2011) . Atypical antipsychotics (clozapine, risperidone, quetiapine, olanzapine, brexpiprazole, aripiprazole) and tricyclic antidepressants (amitriptyline, nortriptyline, imipramine) have a low nanomolar affinity for the α1 receptors (Maeda et al., 2014; Nojimoto et al., 2010; Shapiro et al., 2003) . However, the incidence of orthostatic hypotension for these drugs is low (up to 5% of the patients), decreases upon chronic treatment (Chapple, 2005; Koola et al., 2014) and is handled in the clinic using a dose titration approach (Rieckert, 1996) .
Although much has been done in this work, it is worth mentioning that ACH-000029 was only tested after acute dosing. Thus, chronic studies are still warranted to further explore its anxiolytic potential. In addition, it is well known in the CNS field that psychiatric disorders are difficult to model in animals and that the results obtained do not always translate to the clinic. However, the anxiolytic effects related to the modulation of the mechanisms of action (MoAs) involved here are well documented; drugs such as buspirone (a 5-HT modulator) and prazosin (an α1 adrenergic modulator) are very efficacious both in preclinical models as well as in the clinic. The potential advantage of ACH-000029 is the combination of both MoAs in light of the interplay between the serotonergic and α-adrenergic actions in the brain.
Conclusion
ACH-000029 is a potent and selective modulator of specific 5-HT and NE receptors that exhibits acute anxiolytic-like effects in the lightdark and marble burying tests. The anxiolytic effect was comparable or even better than that of reference drugs used for the treatment of anxiety disorders, such as selective serotonin reuptake inhibitors and benzodiazepines. The c-fos mapping data revealed potential brain regions involved in the anxiolytic effect of ACH-000029. This compound regulated brain regions related to the stress response and processing of environmental stimuli, such as the amygdala, retrosplenial dorsal cortex, pallidum, bed nuclei of the stria terminalis and locus ceruleus. The reported pharmacokinetic data indicates that this compound has adequate brain exposure and oral bioavailability for a psychiatric drug. The absence of withdrawal symptoms after chronic oral administration indicates that ACH-00029 may have a safer profile than selective serotonin reuptake inhibitors and benzodiazepines. Our findings support this compound as a novel, safe and efficacious drug candidate for the treatment of anxiety disorders and motivate its evaluation in additional preclinical anxiety models.
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